Expects to Begin Receiving, Testing and Billing for Patient’s Breast Cancer Tumor Specimens in Q4 2020
DENVER, Colorado — September 9, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical Laboratory Improvement Amendments (CLIA) certification for its Golden, Colorado laboratory, retroactively effective as of January 8, 2020.
The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS) to regulate laboratories that test human specimens. The results of the Colorado CLIA Certification Program survey showed that all CLIA Condition-level requirements were met, adhering to the highest standards in the industry.
“We are thrilled to receive CLIA certification for our Golden, CO laboratory as this was truly a team effort that began two years ago. Receiving CLIA certification is a key step in our growth strategy as we plan to expand our testing capabilities and uncover key insights from human trials in cancer treatment,” said Mick Ruxin, M.D., President and CEO of Theralink Technologies, Inc. “With CLIA certification, we expect to begin receiving, testing and billing for patient’s breast cancer tumor specimens in the fourth quarter of 2020.”
About Theralink® Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado that uniquely specializes in patented, phosphoprotein and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
Theralink Technologies, Inc.
KCSA Strategic Communications
Valter Pinto, Managing Director
Certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or referring to future financial results, patient enrollment and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by OncBioMune Pharmaceuticals with the Securities and Exchange Commission. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business and although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward the forward-looking statements contained herein. The company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.